Summary

at La Jolla, California and other locations
study started
estimated completion:

Description

Summary

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Official Title

Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Keywords

Peripheral T-cell Lymphoma Non-Hodgkins Lymphoma Non-Hodgkin's Lymphoma Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral

Eligibility

You can join if…

  • Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):
  • Aggressive natural killer (NK)-cell leukemia
  • Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
  • Angioimmunoblastic T-cell lymphoma
  • Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
  • PTCL, not otherwise specified (NOS)
  • T/NK-cell lymphoma, nasal type
  • Enteropathy-type intestinal lymphoma
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis T-cell lymphoma
  • Transformed mycosis fungoides (at diagnosis of transformation)
  • T-cell prolymphocytic leukemia (T-PLL)
  • Cutaneous gamma/delta (γ/δ) T-cell lymphoma
  • Cutaneous aggressive CD8+ T-cell lymphoma
  • Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
  • Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
  • Other T-Cell lymphomas that are not listed in the

You CAN'T join if...

  • Patient gives written informed consent

Exclusion Criteria:

  • Patient has other T- or NK-cell malignancies including:
  • Precursor T/NK neoplasms
  • T-cell large granular lymphocytic leukemia
  • Mycosis fungoides, other than transformed mycosis fungoides
  • Sézary syndrome
  • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

Locations

  • Moores Cancer Center UCSD
    La Jolla California United States
  • Wilshire Oncology Medical Group
    La Verne California United States
  • City of Hope National Medical Center
    Duarte California United States
  • UCLA
    Los Angeles California United States
  • USC & Norris Cancer Center
    Los Angeles California United States
  • UCLA Olive View Medical Center
    Sylmar California United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Spectrum Pharmaceuticals, Inc
ID
NCT01110733
Study Type
Observational
Last Updated
April 30, 2018